Immediate Impact

2 from Science/Nature 53 standout
Sub-graph 1 of 24

Citing Papers

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
3 intermediate papers

Works of Kerry A. Rogers being referenced

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia
2020
and 5 more

Author Peers

Author Last Decade Papers Cites
Kerry A. Rogers 1088 857 396 408 121 1.3k
Loïc Ysebaert 892 762 436 424 57 1.3k
Florence Cymbalista 1232 934 489 449 81 1.7k
Deborah M. Stephens 1003 1053 332 346 137 1.6k
Seema A. Bhat 612 530 223 222 67 1.3k
Gerardo Musuraca 509 1193 337 190 81 1.6k
Rémi Letestu 667 527 374 394 52 1.1k
Carlos Panizo 385 518 266 281 91 1.4k
Karim Maloum 1195 907 611 322 50 1.6k
Francesco Cavazzini 696 454 389 382 66 1.3k
Judit Demeter 543 535 262 415 107 1.5k

All Works

Loading papers...

Rankless by CCL
2026